Faes Farma (XMAD:FAE) Stock Based Compensation: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:FAE Faes Farma SA XMAD:FAE
93 GF Score
Price €4.36
GF Value €5.18
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Faes Farma Stock Based Compensation?

Faes Farma XMAD:FAE +0.23% 93 Stock Based Compensation is €0.0 Mil as of Dec. 2025. GuruFocus rates XMAD:FAE with a GF Score™ of 93/100 and a GF Value™ of €5.18 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Faes Farma's Stock Based Compensation for the six months ended in Dec. 2025 was €0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Faes Farma Stock Based Compensation Related Terms

Faes Farma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Faes Farma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faes Farma Stock Based Compensation Chart

Faes Farma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.15 0.77 0.75 0.75

Faes Farma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XMAD:FAE
93GF Score
Faes Farma SA XMAD:FAE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faes Farma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Stock Based Compensation of €0.0 Mil mean?
Faes Farma (XMAD:FAE) has a Stock Based Compensation of €0.0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Faes Farma and its competitors.
Is Faes Farma's Stock Based Compensation too high?
Faes Farma's current Stock Based Compensation is €0.0 Mil. Overall, Faes Farma has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's Stock Based Compensation compare to ZTS and UTHR?
Faes Farma's Stock Based Compensation of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Faes Farma and its competitors. Faes Farma's current Stock Based Compensation is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.18, compared to a current price of €4.36 — trading 15.9% below its estimated fair value. The current Stock Based Compensation is €0.0 Mil. Faes Farma's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current Stock Based Compensation is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Faes Farma (XMAD:FAE) Overvalued in 2026?

Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued. The current stock price of €4.36 is trading 15.9% below its estimated GF Value™ of €5.18. GuruFocus considers Faes Farma to be Modestly Undervalued.

Key valuation signals for XMAD:FAE:

  • Stock Based Compensation: €0.0 Mil
  • GF Value™: €5.18 vs. price of €4.36 (15.9% below fair value)
  • GF Score™: 93/100 with 7 warning signs

No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Faes Farma Business Description

Other Exchanges 0K9H:UKFFEA:Germany
Address Avenida Autonomia, 10, Leioa, Vizcaya, ESP, 48940
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
93GF Score

Get the complete analysis for XMAD:FAE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.36
Price
€5.18
GF Value